目的 探討腦心通膠囊聯(lián)合阿司匹林治療急性心肌梗死的臨床研究。方法 選取2019年9月—2021年1月阜陽市腫瘤醫(yī)院心血管內(nèi)科收治的86例急性心肌梗死患者作為研究對象，按照治療方法將86例患者分為對照組和觀察組，各有43例。對照組口服阿司匹林腸溶片，100 mg/次，1次/d。觀察組在對照組的基礎(chǔ)上口服腦心通膠囊，0.8 g/次，3次/d。兩組均連續(xù)治療4周。觀察兩組患者的臨床療效，同時比較兩組治療前后的纖維蛋白原、血漿黏度、全血高切黏度、D-二聚體和紅細胞壓積（HCT）水平，檢測兩組左室射血分數(shù)（LVEF）、心搏出量（CO）水平。運用WHO生活質(zhì)量量表（WHOQOL）對患者的生活質(zhì)量進行評估。記錄兩組患者不良反應的發(fā)生情況。結(jié)果 治療后，觀察組患者的總有效率為95.35%，顯著高于對照組的81.40%，組間比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組的LVEF、CO均顯著升高（P<0.05）；治療后，觀察組的LVEF、CO顯著高于對照組，差異有統(tǒng)計學意義（P<0.05）。治療后，兩組纖維蛋白原、血漿黏度、全血高切黏度、D-二聚體顯著降低，HCT水平顯著升高（P<0.05）；治療后，觀察組的纖維蛋白原、血漿黏度、全血高切黏度、D-二聚體和HCT水平顯著優(yōu)于對照組，差異有統(tǒng)計學意義（P<0.05）。治療后，兩組的WHOQOL評分均顯著降低（P<0.05），以觀察組降低更明顯（P<0.05）。兩組的藥物不良反應的發(fā)生率無明顯差異。結(jié)論 腦心通膠囊聯(lián)合阿司匹林可提高急性心肌梗死的療效，改善患者血液流變學和心功能，增強生活質(zhì)量，具有良好的療效。

Objective To explore the clinical study of Naoxintong Capsules combined with aspirin in treatment of acute myocardial infarction. Methods A total of 86 patients with acute myocardial infarction admitted to Department of Cardiovascular Medicine (Interventional Treatment Ward), Fuyang Cancer Hospital from September 2019 to January 2021 were selected as the research subjects. According to the treatment methods, the 86 patients were divided into control group and observation group, with 43 patients in each group. Patients in the control group were po administered with Aspirin Enteric-Coated Tablets, 100 mg/time, once daily. Patients in the observation group were po administered with Naoxintong Capsules on the basis of control group, 0.8 g/time, 3 times daily. Both groups were treated continuously for 4 weeks. The clinical efficacy of two groups was observed, and the levels of vitaminogen, plasma viscosity, whole blood high-cut viscosity, D-dimer and hematocentre (HCT) before and after treatment were compared between two groups, and the levels of LVEF and CO were detected between two groups. The quality of life of the patients was evaluated by the WHO Quality of Life Scale (WHOQOL). The incidence of adverse reactions in two groups was recorded. Results After treatment, the total effective rate of observation group was 95.35%, which was significantly higher than 81.40% of control group, and the difference between groups was statistically significant (P < 0.05). After treatment, LVEF and CO in two groups were significantly increased (P < 0.05). After treatment, LVEF and CO in the observation group were significantly higher than those in the control group, with statistical significance (P < 0.05). After treatment, fibrinogen, plasma viscosity, whole blood high-cut viscosity, and D-dimer were significantly decreased in both groups, while HCT level was significantly increased (P < 0.05). After treatment, the levels of fibrinogen, plasma viscosity, whole blood high-cut viscosity, D-dimer and HCT in the observation group were significantly better than those in the control group, with statistical significance (P < 0.05). After treatment, the WHOQOL scores of both groups were significantly decreased (P < 0.05), and the decrease was more obvious in the observation group (P < 0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups. Conclusion Naoxintong Capsules combined with aspirin can improve the curative effect of acute myocardial infarction, improve hemorheology and cardiac function of patients, enhance the quality of life, has a good curative effect.

R972